Anticancer Research · 2022 · 11 citations · 26 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular PharmacologyCardiac PharmacotherapyHormonal Cancer TherapyHormonal TherapyOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityAnticancer ChemotherapyAntineoplastic HormonesCardioprotective TherapyDoxorubicin-based TherapyEstrogen PharmacologyEstrogen ReceptorsTumor Cell Proliferation
BACKGROUND/AIM: About 40% of patients with diffuse large cell lymphoma (DLBCL) still have a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac failure. Growing evidence suggests an antitumor and cardioprotective activity exerted by estrogen via its binding to estrogen receptor (ER) β. The aim of this study was to evaluate the anticancer activity of the phytoestrogen silibinin, an ERβ selective agonist, on DLBCL growth, and its potential cardioprotective effect. MATERIALS AND METHODS: DLBCL cell lines SUDHL-8, SUDHL-6, and RIVA were used. The anti-tumor activity of silibinin was also evaluated in vivo in NOD/SCID/IL2Rg-/- (NSG) xenografted mice. AC16 human ventricular cardiomyocytes were used to investigate the cardioprotective effects of silibinin. RESULTS: In vitro silibinin induced apoptosis and autophagy, and blocked tumor cell proliferation, also protecting AC16 cardiomyocytes from doxorubicin-induced toxicity. In vivo silibinin induced cell death and autophagy, and reduced tumor volume. CONCLUSION: Silibinin represents a promising therapeutic tool.
26
Anticancer potential of silymarin: from bench to bed side.
Rajesh Agarwal, Charu Agarwal, Haruyo Ichikawa et al. · PubMed · 2007 · 293 citations
Medicine, Oncology, Pharmacology +13
Paola Matarrese, Antonella Tinari, Elisabetta Mormone et al. · Journal of Biological Chemistry · 2004 · 179 citations · Full text